ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure (PARACYS-RV)

University of Montreal

Status: Terminated

Conditions: Systemic Right Ventricle; Heart Failure

Treatments: Drug: Placebo; Drug: Sacubitril / Valsartan Oral Tablet

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05117736

ICM 2021-2942

Details and patient eligibility

About

This study is a prospective monocentric, randomized, double-blind, placebo-controlled, crossover clinical trial to assess the efficacy of Sacubitril/Valsartan over placebo in improving exercise capacity and neurohormonal activation in adults with moderate to severe systemic RV dysfunction and NYHA class II or III symptoms.

Full description

Subjects who qualify will be approached and those consenting will be enrolled to undergo a baseline evaluation. An active run-in-phase of 6 weeks will identify each patient's maximal tolerated dose of Sacubitril/Valsartan. Then, each treatment arm (Sacubitril/Valsartan and placebo) will be 24 weeks duration prior to crossover. At the end of each study arm (24 weeks), data regarding primary and secondary endpoints will be collected. The total duration of the study for the patient will be 15 months.

Subjects will undergo regular visits (in-clinic, and/or by phone, or video conferencing) half-way and at the end of each arms.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > or egal18 years with clinical follow-up at the Montreal Heart Institute Adult Congenital Heart Center
• Systemic right ventricle (transposition of great vessels and atrial switch or congenitally corrected transposition of great vessels)
• Moderate to severe systemic right ventricle dysfunction by transthoracic echocardiography (TTE) or right ventricle ejection fraction (RVEF) <40% by MRI
• NYHA Functional class II-III symptoms or peak exercise capacity <80% of predicted on a previous standard treadmill exercise stress test (usually done every two years in our congenital clinic).
• Ability to provide informed consent to the study
• Access or own a telephone and/or access to internet connection for teleconference call
• Own a mailing address to receive the medication by post (FedEx or Dicom)
• Able to perform self-measurement of the blood pressure using Upper Arm Digital Blood Pressure Monitor as recommended by Hypertension Canada.

Exclusion criteria

• Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days prior enrolment
• Planned cardiac surgery (e.g., severe tricuspid regurgitation with planned tricuspid valve replacement or repair)
• Previous cardiac transplantation, or on heart transplant wait list
• Myocardial infarction, stroke, or open-heart surgery in the previous 4 weeks
• NYHA Functional class I or IV symptoms
• Symptomatic hypotension (fainting, dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache) with a systolic blood pressure <100 mmHg at screening, or asymptomatic <90 mmHg at screening
• eGFR <30 mL/min/1.73 m2
• Reduction in eGFR >35% from screening to randomization
• Potassium >5.2 mmol/L at screening or >5.4 mmol/L at randomization
• Known history of angioedema related to previous ACEI or ARB therapy or patients with a history of hereditary or idiopathic angioedema.
• Patients who require concomitant treatment with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) or a renin inhibitor for other indication than heart failure
• Evidence of hepatic disease as determined by any one of the following: serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) values exceeding 3x upper limit of normal, bilirubin >1.5 mg/dl at screening.
• Unacceptable side effects with ACE-inhibitors or ARBs
• Patient known with bilateral renal artery stenosis
• Cyanosis; substantial left-to-right shunting (Qp/Qs >1.5); severe mitral, aortic, or pulmonary regurgitation; systemic or pulmonary inflow obstruction with a peak velocity >1.5 m/s by transthoracic echocardiography; and severe outflow tract obstruction with a peak systolic gradient >80 mm Hg.
• Inability to provide informed consent
• Unable to exercice
• Pregnant or planned pregnancy during the study
• Breastfeeding
• Severe pulmonary hypertension defined as pulmonary pressure egal or superior to systemic pressure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

15 participants in 2 patient groups, including a placebo group

Sacubitril/Valsartan

Experimental group

Description:

Treatment with Sacubitril/Valsartan

Treatment:

Drug: Sacubitril / Valsartan Oral Tablet

Placebo

Placebo Comparator group

Description:

Treatment with Placebo

Treatment:

Drug: Placebo